Navigation Links
MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Date:8/6/2012

KENNESAW, Ga., Aug. 6, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company has raised over $4.9 million through the exercise of Callable Warrants issued in conjunction with the October 2010 Private Placement.

The Company exercised its right to redeem the Warrants effective August 3, 2012.  Holders had the option to exercise the Warrants or have them redeemed by the Company.  Over 98% of the Callable Warrants were exercised. 

Parker H. "Pete" Petit, Chairman and CEO, said, "The exercise of these Warrants is a 'win-win' for the Company and our investors, as it strengthens our balance sheet, and provides a nice return for the holders.  The Company intends to use the proceeds for general operating needs, including additional clinical trials, as well as the addition of some key direct sales force hires.  These hires will also help expedite our strategy to expand our direct sales representatives and move  toward a blended sales force."

Cancellation of Second Contingent Warrants

The Company also announced the cancellation of approximately 3.2 million Second Contingent Warrants.  The Warrants had been issued to holders that invested in the Company's October 2010 Private Placement and the Senior Secured Promissory Notes issued in December 2011.  More details regarding the terms of the private placement and warrants are disclosed in the Company's SEC filings.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal its
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
2. MiMedx Group Announces Record Second Quarter Results
3. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
4. MiMedx Group Announces Record First Quarter Results
5. MiMedx Exceeds Revenue Goal for First Quarter of 2012
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Group Announces 2011 Results
8. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
9. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
10. MiMedx Group Completes $5,000,000 Private Placement
11. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  On May 9, 2013, FTI ... global business advisory firm dedicated to helping organizations ... announced that it has combined the healthcare and ... within the Corporate Finance/Restructuring segment with those in ... a single integrated practice whose financial results and ...
(Date:5/21/2013)... YORK , May 21, 2013  The Lindsley F. ... today that it is a Grand Challenges Explorations ... Gates Foundation .  Dr. Sara Lustigman , ... innovative global health and development research project, titled Innovative ...  These worms are needed to screen drugs to help ...
(Date:5/21/2013)... May 21, 2013 Custom Learning ... reporting eLearning solution using Tin Can API combined ... tool. CLD is a leading developer of training ... device companies worldwide. , Tin Can API ... helps learners and trainers more accurately measure the ...
(Date:5/21/2013)... Through science fairs, workshops, kits for building optical ... organizations will continue their work to increase awareness about ... daily life with the aid of SPIE Education ... countries, are the first of two groups of recipients ... international society for optics and photonics , in 2013. ...
Breaking Biology Technology:FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3
... onset seizure reduction, proven tolerability, and ... - Keppra XR(TM) is built on ... regulated information:,UCB announced today that the U.S. Food and Drug ... as,an add-on to other antiepileptic treatments for people with partial-onset,seizures ...
... 12 Exosome Diagnostics, Inc. today,announced the appointment ... In this role, Dr. Skog will oversee the ... blood-based diagnostics that can,identify cancer-specific genetic mutations., ... of Exosome Diagnostics,core technology that has been licensed ...
... - Upfront, milestone payments and promotional investment totaling up to ... ... 12 CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today ... Ranexa(R) (ranolazine prolonged release,tablets) in Europe and other countries to ...
Cached Biology Technology:Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 2CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 3CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 5
(Date:5/20/2013)... planning grant will help establish the Center for Advanced ... University of Illinois at Urbana-Champaign and Worcester Polytechnic Institute ... to research in drying moist, porous materials such as ... chemical products; textiles; and biopharmaceuticals," said Hao Feng, a ... nutrition and the Illinois site director. , According to ...
(Date:5/20/2013)... the University of Bristol and published online today in ... on how the brain and inner ear developed in ... Earth Sciences, together with Tom Hbner from the Niederschsische ... million year old dinosaurs. , The two palaeontologists studied ... : a very young (juvenile) individual of approximately ...
(Date:5/19/2013)... white men and women of European descent inherit common ... toe deformities, including hammer or claw toe. Findings from ... of foot disorders in humansappear in Arthritis Care ... behalf of the American College of Rheumatology (ACR). ... of older adults have foot disorders which may limit ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2Blame your parents for bunion woes 2
... Highlights: Advanced technologies create ... Radio was integrated easily with Army,s cellular biometric network ... Harris Corporation,s (NYSE: HRS ... infrastructure for various mission scenarios at the Empire Challenge 2011 ...
... 2011 Ceelox, Inc., (OTCBB: CELO), (the "Company"), proudly ... the U.S. Patent Office. The patent, U.S. Patent Number ... Encryption And Decryption" provides the ability to biometrically enable ... data.  Ceelox, latest patent is unique in that it ...
... study from scientists at Queen Mary, University of London, sheds ... go through major surgery, can suffer organ damage in parts ... The study, published today in Nature Immunology *, ... out of blood vessels to defend damaged organs against injury ...
Cached Biology News:Harris Corporation's Highband Networking Radio Provides Mobile, Wideband Communications for Empire Challenge 2011 2Harris Corporation's Highband Networking Radio Provides Mobile, Wideband Communications for Empire Challenge 2011 3Ceelox Vault Patent Issued 2Ceelox Vault Patent Issued 3Rogue blood cells may contribute to post-surgery organ damage 2
... research laboratory, the revolutionary Luminex 100 System ... and in real time enhancing your operational ... includes the Luminex 100, the XY Platform, ... which enables you to simultaneously assay up ...
... is a compact analysis system for the clinical ... a controller, advanced digital signal processing and a ... system includes the Luminex 100, the XY Platform, ... file at the FDA, and partner kits that ...
... quality source of amino acids and ... of casein. It is recommended for ... been used in antibiotics, toxins and ... For microbiology pH6.8 0.5 at 25 ...
... peptone, used in media ... bacterial toxins, and for ... with high nutritional requirements ... Pasteurella, Salmonella and Staphylococcus ...
Biology Products: